ConferenceCirculation · November 4, 2025
Background:
Although it is known that increased urinary protein excretion is predictive of both end-stage kidney disease and cardiovascular (CV) outcomes, laboratory quantification of ...
Full textCite
ConferenceCirculation · November 4, 2025
Background:
Lactate dehydrogenase (LDH) is a cytoplasmic enzyme found in most cells that catalyses the forward and backwards conversion of pyruvate to lactate. Tissue LDH concentration ...
Full textCite
ConferenceCirculation · November 12, 2024
Introduction:
The selective cardiac myosin activator, omecamtiv mecarbil (OM), has been shown to benefit individuals with HFrEF but the clinical experience of cardiac myosin activators and incidence o ...
Full textCite
ConferenceCirculation · November 12, 2024
Background:
Older age is associated with a high prevalence of comorbidities and worse cardiovascular (CV) outcomes in patients with heart failure with reduced ejection fraction (HFrEF). Omecamtiv meca ...
Full textCite
ConferenceAm Heart J · September 2023
BACKGROUND: Electronic health record (EHR)-based identification of heart failure with preserved ejection fraction (HFpEF) in the clinical setting may facilitate screening for clinical trials by improving the understanding of its epidemiology and outcomes; ...
Full textLink to itemCite
ConferenceJ Am Heart Assoc · September 7, 2021
Background Contemporary trials of patients with heart failure with reduced ejection fraction (HFrEF) required a recent worsening heart failure (WHF) event for inclusion. We aimed to describe characteristics and outcomes of patients with HFrEF and a recent ...
Full textLink to itemCite
ConferenceJACC Heart Fail · January 2021
BACKGROUND: Treatment of heart failure with reduced ejection fraction (EF) may improve patient-reported health outcomes. OBJECTIVES: The purpose of this study was to determine timing and magnitude of change in Kansas City Cardiomyopathy Questionnaire (KCCQ ...
Full textLink to itemCite
ConferenceCirculation · November 17, 2020
Background:
The prognostic implications of achieving NT-proBNP concentrations ≤1000 pg/mL among obese patients having heart failure with reduced ejection fraction (HFrEF) are not completely known. We ...
Full textCite
ConferenceJ Am Heart Assoc · December 18, 2018
Background We sought to study the prevalence of high-sensitivity troponin and its association with cardiac structure and outcomes in ambulatory and hospitalized patients with heart failure with a preserved ejection fraction ( HF p EF ). Methods and Results ...
Full textLink to itemCite
ConferenceESC Heart Fail · December 2018
AIMS: Obesity is present in up to 45% of patients with heart failure (HF). Liraglutide, a glucagon-like peptide-1 (GLP-1) receptor antagonist, facilitates weight loss in obese patients. The efficacy of liraglutide as a weight loss agent among patients with ...
Full textLink to itemCite
ConferenceCirc Heart Fail · June 2017
BACKGROUND: Daily physical activity assessed by accelerometers represents a novel method to assess the impact of interventions on heart failure (HF) patients' functional status. We hypothesized that daily activity varies by patient characteristics and corr ...
Full textLink to itemCite
Conference · 2017
Introduction: It is unclear whether multi-marker approaches improve risk stratification among patients with heart failure (HF). We evaluated the prognostic utility of a multi-marker approach with biomarkers of HF status; Growth-differentiation factor-15 (G ...
Cite
